Aptalis Pharmaceutical Technologies is now Adare Pharmaceuticals
On April 1, 2015, Aptalis Pharmaceutical Technologies was divested from Actavis plc (NYSE: ACT) to TPG, a global private investment firm. The company’s new name is Adare Pharmaceuticals. Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health.
On April 1, 2015, Aptalis Pharmaceutical Technologies was divested from Actavis plc (NYSE: ACT) to TPG, a global private investment firm. The company’s new name is Adare Pharmaceuticals.
Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health.
Building upon our legacy, we strive to reshape medicines tailored to the needs of the evolving global healthcare market. Through internal development and the acquisition of new technologies and products, we will expand our pipeline and capabilities to deliver greater value to partners and patients.
For decades, we have solved complex formulation, manufacturing and commercialization challenges, resulting in transformational medicines that deliver value to all our stakeholders.
We see opportunities for transforming medicines where others cannot because of our proprietary technologies, as well as our employees’ expertise and experience in R&D, manufacturing complex products and commercialization.
More than ever before, we have the vision, resources and talent, making the company uniquely suited to unlock the potential of more medicines, helping patients to maximize the benefit of their treatments.
For more information, contact Lisa.Miller@adarepharma.com or visit www.AdarePharma.com
©2015 Adare Pharmaceuticals, Inc.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
